Diamyd Medical Receives U.S. FDA Fast Track Designation for Diamyd®
Diamyd Medical announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd® (rhGAD65/alum), a treatment under investigation for improving glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2. The Fast Track designation aims to facilitate the development and expedite the review of medicines that treat serious conditions and fill an unmet medical need, with the goal of bringing promising medicines to patients sooner.
Ulf Hannelius, CEO of Diamyd Medical, expressed enthusiasm about the FDA's decision, stating, "We are very pleased with the FDA's decision to grant Fast Track designation for Diamyd and the potential this provides to accelerate Diamyd's path to entering the US market." He emphasized the significance of Diamyd in the shift towards personalized medicine in the treatment of Type 1 Diabetes, offering new hope beyond traditional insulin therapy.
The treatment paradigm for Type 1 Diabetes is evolving towards precision medicine due to the limitations of current treatment options, which often fail to consistently achieve glycemic targets and are associated with short- and long-term complications. Diamyd® represents a new therapeutic approach that has shown promising results in preserving pancreatic beta cell function and improving glycemic control in individuals with Type 1 Diabetes. Clinical trials have demonstrated Diamyd®'s potential to safely modulate the immune system's response against pancreatic beta cells, aiming to halt or slow the disease's progression.
Diamyd® is currently being evaluated in the DIAGNODE-3 trial, a confirmatory Phase III trial in individuals recently diagnosed with Type 1 Diabetes carrying the HLA DR3-DQ2 genotype. The trial is ongoing in the United States and eight European countries, aiming to enroll up to 330 individuals aged 12 to 29 years. The trial design is based on clinical efficacy and safety results from previous Phase IIa and Phase IIb trials, as well as a large-scale meta-analysis encompassing data from over 600 individuals.
Diamyd Medical is focused on developing precision medicine therapies for the prevention and treatment of Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd® has Orphan Drug Designation in the U.S. and was granted Fast Track designation by the U.S. FDA in February 2024. The company is also developing the GABA-based investigational drug Remygen® for the treatment of metabolic diseases and holds significant investments in the stem cell company NextCell Pharma AB and the artificial intelligence company MainlyAI AB.